The global increti-based drugs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of chronic diseases such as diabetes and obesity, which are major drivers for incretin-based drugs. The oral drugs segment accounted for the largest share in the global increti-based drugs market in 2018, followed by injectable drugs and then by application. Oral drug segment accounted for more than 50% share in 2018 due to its wide range of applications such as type 2 diabetes mellitus (T2DM) and obesity.
Some Of The Growth Factors Of This Market:
- In addition, the rising number of patients with type 2 diabetes who are not responding well to oral antidiabetic agents is also expected to fuel demand for incretin-based drugs in the near future.
- Furthermore, technological advancements in drug delivery systems such as inhalers and nasal sprays have increased patient compliance rates and reduced side effects associated with these medications which has led to an increase in their usage over time .
Industry Growth Insights published a new data on “Incretin-Based Drugs Market”. The research report is titled “Incretin-Based Drugs Market research by Types (Glucagon-like peptide-1 receptor (GLP-1) agonists, Dipeptidyl Peptidase-4 (DPP-4) inhibitors), By Applications (Oral Drugs, Injectable Drugs), By Players/Companies GlaxoSmithKline, Johnson & Johnson, Merck & Co, AstraZeneca, Novartis, Eli Lilly and Company, Boehringer Ingelheim, Takeda Pharmaceutical Company, Sanofi”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Incretin-Based Drugs Market Research Report
By Type
Glucagon-like peptide-1 receptor (GLP-1) agonists, Dipeptidyl Peptidase-4 (DPP-4) inhibitors
By Application
Oral Drugs, Injectable Drugs
By Companies
GlaxoSmithKline, Johnson & Johnson, Merck & Co, AstraZeneca, Novartis, Eli Lilly and Company, Boehringer Ingelheim, Takeda Pharmaceutical Company, Sanofi
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Incretin-Based Drugs Market Report Segments:
The global Incretin-Based Drugs market is segmented on the basis of:
Types
Glucagon-like peptide-1 receptor (GLP-1) agonists, Dipeptidyl Peptidase-4 (DPP-4) inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oral Drugs, Injectable Drugs
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Co
- AstraZeneca
- Novartis
- Eli Lilly and Company
- Boehringer Ingelheim
- Takeda Pharmaceutical Company
- Sanofi
Highlights of The Incretin-Based Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Glucagon-like peptide-1 receptor (GLP-1) agonists
- Dipeptidyl Peptidase-4 (DPP-4) inhibitors
- By Application:
- Oral Drugs
- Injectable Drugs
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Incretin-Based Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Incretin-based drugs are medications that work by stimulating the release of incretins from the pancreas. These drugs are often used to treat type 2 diabetes, and they can also be used to manage other health conditions, such as obesity or high blood pressure.
Some of the key players operating in the incretin-based drugs market are GlaxoSmithKline, Johnson & Johnson, Merck & Co, AstraZeneca, Novartis, Eli Lilly and Company, Boehringer Ingelheim, Takeda Pharmaceutical Company, Sanofi.
The incretin-based drugs market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Incretin-Based Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Incretin-Based Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Incretin-Based Drugs Market - Supply Chain
4.5. Global Incretin-Based Drugs Market Forecast
4.5.1. Incretin-Based Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Incretin-Based Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Incretin-Based Drugs Market Absolute $ Opportunity
5. Global Incretin-Based Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Incretin-Based Drugs Market Size and Volume Forecast by Type
5.3.1. Glucagon-like peptide-1 receptor (GLP-1) agonists
5.3.2. Dipeptidyl Peptidase-4 (DPP-4) inhibitors
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Incretin-Based Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Incretin-Based Drugs Market Size and Volume Forecast by Application
6.3.1. Oral Drugs
6.3.2. Injectable Drugs
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Incretin-Based Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Incretin-Based Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Incretin-Based Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Incretin-Based Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Incretin-Based Drugs Demand Share Forecast, 2019-2026
9. North America Incretin-Based Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Incretin-Based Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Incretin-Based Drugs Market Size and Volume Forecast by Application
9.4.1. Oral Drugs
9.4.2. Injectable Drugs
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Incretin-Based Drugs Market Size and Volume Forecast by Type
9.7.1. Glucagon-like peptide-1 receptor (GLP-1) agonists
9.7.2. Dipeptidyl Peptidase-4 (DPP-4) inhibitors
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Incretin-Based Drugs Demand Share Forecast, 2019-2026
10. Latin America Incretin-Based Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Incretin-Based Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Incretin-Based Drugs Market Size and Volume Forecast by Application
10.4.1. Oral Drugs
10.4.2. Injectable Drugs
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Incretin-Based Drugs Market Size and Volume Forecast by Type
10.7.1. Glucagon-like peptide-1 receptor (GLP-1) agonists
10.7.2. Dipeptidyl Peptidase-4 (DPP-4) inhibitors
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Incretin-Based Drugs Demand Share Forecast, 2019-2026
11. Europe Incretin-Based Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Incretin-Based Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Incretin-Based Drugs Market Size and Volume Forecast by Application
11.4.1. Oral Drugs
11.4.2. Injectable Drugs
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Incretin-Based Drugs Market Size and Volume Forecast by Type
11.7.1. Glucagon-like peptide-1 receptor (GLP-1) agonists
11.7.2. Dipeptidyl Peptidase-4 (DPP-4) inhibitors
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projetions by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Incretin-Based Drugs Demand Share, 2019-2026
12. Asia Pacific Incretin-Based Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Incretin-Based Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Incretin-Based Drugs Market Size and Volume Forecast by Application
12.4.1. Oral Drugs
12.4.2. Injectable Drugs
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Incretin-Based Drugs Market Size and Volume Forecast by Type
12.7.1. Glucagon-like peptide-1 receptor (GLP-1) agonists
12.7.2. Dipeptidyl Peptidase-4 (DPP-4) inhibitors
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Incretin-Based Drugs Demand Share, 2019-2026
13. Middle East & Africa Incretin-Based Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Incretin-Based Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Incretin-Based Drugs Market Size and Volume Forecast by Application
13.4.1. Oral Drugs
13.4.2. Injectable Drugs
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Incretin-Based Drugs Market Size and Volume Forecast by Type
13.7.1. Glucagon-like peptide-1 receptor (GLP-1) agonists
13.7.2. Dipeptidyl Peptidase-4 (DPP-4) inhibitors
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Incretin-Based Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Incretin-Based Drugs Market: Market Share Analysis
14.2. Incretin-Based Drugs Distributors and Customers
14.3. Incretin-Based Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GlaxoSmithKline
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Johnson & Johnson
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Merck & Co
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. AstraZeneca
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novartis
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Eli Lilly and Company
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Boehringer Ingelheim
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Takeda Pharmaceutical Company
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Sanofi
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
